Nadia Demarteau

Summary

Affiliation: GlaxoSmithKline Biologicals
Country: Belgium

Publications

  1. pmc Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
    Michele Kohli
    OptumInsight, Health Economics and Outcomes Research, 5500 North Service Rd, Burlington, ON L7L 6W6, Canada
    BMC Public Health 12:872. 2012
  2. ncbi request reprint Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium
    Nadia Demarteau
    Health Economics, GlaxoSmithKline Vaccines, Rue Fleming 20, B 1300 Wavre, Belgium
    Vaccine 31:3962-71. 2013
  3. ncbi request reprint Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan
    Nadia Demarteau
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Value Health 15:622-31. 2012
  4. ncbi request reprint Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program
    Nadia Demarteau
    Health Economics, Global Vaccine Development, GlaxoSmithKline Biologicals, Wavre, Belgium
    Pharmacoeconomics 30:337-53. 2012
  5. pmc A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females
    Andrea M Anonychuk
    Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
    BMC Public Health 9:401. 2009
  6. pmc Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models
    Mark Jit
    Modelling and Economics Unit, Health Protection Agency, London, UK
    BMC Med 9:54. 2011
  7. pmc A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer
    Nadia Demarteau
    Health Economics, GlaxoSmithKline Biologicals, Wavre, Belgium
    Int J Public Health 56:153-62. 2011
  8. ncbi request reprint Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer
    Nadia Demarteau
    Health Economics, GlaxoSmithKline Biologicals, Av Fleming 20, Wavre, Belgium
    J Med Econ 13:324-38. 2010
  9. ncbi request reprint Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models?
    Baudouin Standaert
    Health Economics, GlaxoSmithKline Biologicals, Parc de la Noire Epine, B 1300 Wavre, Belgium
    Vaccine 28:G30-8. 2010
  10. ncbi request reprint Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths
    Georges Van Kriekinge
    Health Economics, GlaxoSmithKline Vaccines, Avenue Fleming, 20, Wavre, 1300, Belgium Electronic address
    Vaccine 32:733-9. 2014

Collaborators

Detail Information

Publications10

  1. pmc Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
    Michele Kohli
    OptumInsight, Health Economics and Outcomes Research, 5500 North Service Rd, Burlington, ON L7L 6W6, Canada
    BMC Public Health 12:872. 2012
    ..In this analysis, the estimated clinical and economic benefit of each of these vaccines was compared in the Canadian setting...
  2. ncbi request reprint Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium
    Nadia Demarteau
    Health Economics, GlaxoSmithKline Vaccines, Rue Fleming 20, B 1300 Wavre, Belgium
    Vaccine 31:3962-71. 2013
    ..The role of protection against non-HPV-16/18 was also investigated...
  3. ncbi request reprint Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan
    Nadia Demarteau
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Value Health 15:622-31. 2012
    ....
  4. ncbi request reprint Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program
    Nadia Demarteau
    Health Economics, Global Vaccine Development, GlaxoSmithKline Biologicals, Wavre, Belgium
    Pharmacoeconomics 30:337-53. 2012
    ..Neither alone can provide 100% protection. Consequently it raises the important question about the most efficient combination of screening at specified time intervals and vaccination to prevent cervical cancer...
  5. pmc A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females
    Andrea M Anonychuk
    Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
    BMC Public Health 9:401. 2009
    ..This study estimates the effectiveness and cost-effectiveness of vaccinating 12-year old Canadian females with an AS04-adjuvanted cervical cancer vaccine. The indirect effect of vaccination, via herd immunity, is also estimated...
  6. pmc Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models
    Mark Jit
    Modelling and Economics Unit, Health Protection Agency, London, UK
    BMC Med 9:54. 2011
    ..To provide information about the feasibility of using such models in a developing country setting, we evaluated models of HPV vaccination in terms of their capacity, requirements, limitations and comparability...
  7. pmc A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer
    Nadia Demarteau
    Health Economics, GlaxoSmithKline Biologicals, Wavre, Belgium
    Int J Public Health 56:153-62. 2011
    ..This study aimed at evaluating the cost-effectiveness of human papillomavirus virus (HPV) vaccination in France, using a generally applicable succinct cohort model...
  8. ncbi request reprint Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer
    Nadia Demarteau
    Health Economics, GlaxoSmithKline Biologicals, Av Fleming 20, Wavre, Belgium
    J Med Econ 13:324-38. 2010
    ..Two human papillomavirus (HPV) vaccines are on the market. Based on expected differences in sustained- and cross-protection between the two vaccines, their long-term economic value is modelled and compared for France, Ireland and Italy...
  9. ncbi request reprint Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models?
    Baudouin Standaert
    Health Economics, GlaxoSmithKline Biologicals, Parc de la Noire Epine, B 1300 Wavre, Belgium
    Vaccine 28:G30-8. 2010
    ....
  10. ncbi request reprint Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths
    Georges Van Kriekinge
    Health Economics, GlaxoSmithKline Vaccines, Avenue Fleming, 20, Wavre, 1300, Belgium Electronic address
    Vaccine 32:733-9. 2014
    ..Mathematical models have estimated the potential real-life impact of vaccination on the burden of cervical cancer (CC). However, these are restricted to evaluations in a limited number of countries...